Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Eptacog alfa activated
400,000units
B02BD08
Eptacog alfa activated
400000unit
Powder and solvent for solution for injection
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: ; GTIN: 5017954001958
1 PACKAGE LEAFLET: INFORMATION FOR THE USER NOVOSEVEN ® 1 MG (50 KIU) 2 MG (100 KIU) 5 MG (250 KIU) 8 MG (400 KIU) POWDER AND SOLVENT FOR SOLUTION FOR INJECTION eptacog alfa (activated) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS INJECTION BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. WHAT NOVOSEVEN ® IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU USE NOVOSEVEN ® 3. HOW TO USE NOVOSEVEN ® 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE NOVOSEVEN ® 6. CONTENTS OF THE PACK AND OTHER INFORMATION OVERLEAF: Instructions on how to use NovoSeven ® 1. WHAT NOVOSEVEN ® IS AND WHAT IT IS USED FOR NOVOSEVEN ® IS A BLOOD COAGULATION FACTOR. It works by making the blood clot at the site of bleeding, when the body's own clotting factors are not working. NOVOSEVEN ® IS USED to treat bleeding, and to prevent excessive bleeding after surgery or other important treatments. Early treatment with NovoSeven ® reduces how much you bleed and for how long. It works in all types of bleeds, including joint bleeds. This reduces the need for hospitalisation and days absent from work and school. It is used in certain groups of people: • If you were _BORN WITH HAEMOPHILIA_ and do not respond normally to factors VIII or IX treatment • If you have _ACQUIRED HAEMOPHILIA_ • If you have _FACTOR VII DEFICIENCY_ • If you have _GLANZMANN’S THROMBASTHENIA_ (a bleeding disorder) and your condition cannot be treated effectively with platelet transfusion. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE NOVOSEVEN ® DO NOT USE NOVOSEVEN ® • If you are ALLERGIC TO EPTACOG ALFA (active compound Read the complete document
OBJECT 1 NOVOSEVEN 1 MG (50KIU) POWDER AND SOLVENT FOR SOLUTION FOR INJECTION Summary of Product Characteristics Updated 20-Jan-2017 | Novo Nordisk Limited 1. Name of the medicinal product NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection 2. Qualitative and quantitative composition NovoSeven 1 mg (50 KIU) NovoSeven is presented as powder and solvent for solution for injection containing 1 mg eptacog alfa (activated) per vial (corresponds to 50 KIU/vial). NovoSeven 2 mg (100 KIU) NovoSeven is presented as powder and solvent for solution for injection containing 2 mg eptacog alfa (activated) per vial (corresponds to 100 KIU/vial). NovoSeven 5 mg (250 KIU) NovoSeven is presented as powder and solvent for solution for injection containing 5 mg eptacog alfa (activated) per vial (corresponds to 250 KIU/vial). NovoSeven 8 mg (400 KIU) NovoSeven is presented as powder and solvent for solution for injection containing 8 mg eptacog alfa (activated) per vial (corresponds to 400 KIU/vial). 1 KIU equals 1,000 IU (International Units). Eptacog alfa (activated) is recombinant coagulation factor VIIa (rFVIIa) with a molecular mass of approximately 50,000 Daltons produced in baby hamster kidney cells (BHK Cells) by recombinant DNA technology. After reconstitution, the product contains 1 mg/ml eptacog alfa (activated) when reconstituted with solvent. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Powder and solvent for solution for injection. White lyophilised powder. Solvent: clear colourless solution. The reconstituted solution has a pH of approximately 6.0. 4. Clinical particulars 4.1 Therapeutic indications NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following pat Read the complete document